Neurentis plc

#Diet and #depression: unveiling the multiple roles of #nutrients in the #cellular #crosstalk Close your eyes and locate yourself on a space shuttle, ready to leave for an exploratory mission 🚀 … Be aware that your destination will not be outside of the Earth, in the infinitely big, but inside the cell, in the infinitely small! 👩🚀 Possibly you will end up against some mitochondria, ribosomes, endoplasmic reticulum, until trapped in the cytoskeleton… But you would have the privilege to unveil the signalling across different compartments or from cell to cell. Upon #food ingestion, with nutrients orchestrating all these interactions, the magic begins 💫 Let’s focus on depression as a model of interaction: ✅ #Inflammation: observational studies and clinical trials confirm that the Mediterranean diet works best on systemic inflammation, due to the abundance of dietary fibers, vitamins, polyphenols and Omega-3 fatty acids, beneficial against mental disorders. ✅ #Oxidative #stress: ROS and NOS lead to #mitochondrial #dysfunction, inflammation, and altered tryptophan metabolism, which are all implicated in mental health disorders. Western diets increase markers of oxidative stress, protein damage and lipid peroxidation. Vitamin C and E are strong free radical scavengers. Selenium, zinc and cysteine are cofactors for GPx and SOD. N-acetyl cysteine contributes to alleviate depressive symptoms. ✅ #Gut #Microbiota: it controls depression through inflammation, gut permeability, neurogenesis, tryptophan metabolism and SCFAs release. Western diets from animal models increase the abundance of Clostridiales, Ruminococcaceae, and Bacteroidales, with poorer cognitive reactions and social behaviors. #Prebiotics (FOS and GOS) reverse chronic stress-induced alterations normalizing pro-inflammatory cytokines and depressive symptoms. ✅ The hypothalamic–pituitary–adrenal (#HPA) Axis: More than 60% depressed people report #cortisol production in excess. Omega-3 fatty acid, pomegranate juice and dark chocolate improve cortisol levels in healthy and depressed people, according to separate studies. ✅ #Neurogenesis and #BDNF: as part of the PREDIMED study, Mediterranean diet supplemented with nuts showed higher level of plasma BDNF compared to the control. Calorie restriction or intermittent fasting also influence BDNF release, while Western diet impairs hippocampal-dependent learning and memory. ✅ #Epigenetics: vitamins (folate, biotin, B6 and B12), #polyphenols (curcumin, resveratrol and genistein) and omega3 fatty acids influence gene expression. What about #SCFAs? #Butyrate, as HDAC inhibitor, exerts an impact on histone modifications and transcriptional regulation. #Nutritional #Psychiatry represents a new frontier for targeted strategies preventing or treating #mental #illness. Unveiling the complexity beneath molecular interactions is our prerogative to fully appreciate the therapeutic value of food. Link: https://lnkd.in/ddfW98Bf

Cardiovascular Exercise Enhances Brain function. In a study just published in the Journal of Physiology, researchers have unraveled the intricate connection between acute cardiovascular exercise and cognitive performance, specifically the reduction in reaction time (RT). The Core Discovery Utilizing advanced [11C]raclopride positron emission tomography (PET), the study showcased a remarkable correlation between acute physical exercise and the release of endogenous dopamine (DA) in the brain. This internal release of DA was not only proven but directly linked to improvements in reaction time, as observed in the Go/No-Go task. Decoding the Mechanism To dig deeper into the triggers for reaction time improvement, the study incorporated two electrical muscle stimulation (EMS) experiments. The results were clear: RT improved significantly with EMS involving moderate arm cranking. This highlighted a crucial point – the alteration in reaction time is intricately tied to central signals from higher brain centers, not just peripheral muscle contractions. Key Takeaways Dopamine's Role - The study positions endogenous dopamine as a pivotal neuromodulator in enhancing reaction time. Central Signals Matter - Exercise's impact on RT is not merely about movement but is significantly influenced by central signals originating from higher brain centers. Why It Matters Beyond the scientific intrigue, this discovery carries profound implications for understanding how our brains swiftly adapt behaviour using neuromodulatory systems. It's not just a boost in physical performance; it's a profound insight into optimising cognitive health. Read the scientific abstract here (https://lnkd.in/d_824gmz) for the symbiotic relationship between exercise and cognitive health. #brainscience #cognitive #cognitivehealth #dopamine #exercise #exerciseismedicine #neurentis #neuroscience #neuroscienceresearch #researchanddevelopment #research #brainhealth #psychiatry #depression #mentalhealth #health #brainresearch #neurology #dementia #lifesciences #medicine

Big Pharma Continues to Bet Big on Neuroscience! Bristol Myers Squibb announced a $14 billion acquisition of Karuna Therapeutics, following closely on another very recent neuroscience transaction, AbbVie’s $8.7 billion deal with Cerevel Therapeutics. These substantial investments reaffirm the pharmaceutical industry’s strong focus on groundbreaking neuroscience treatments. This series of acquisitions signifies a significant trend in major pharmaceutical players seeking to secure innovative solutions in the field of neuroscience. Stay tuned for further updates as Neurentis remains at the forefront of this transformative era, contributing to the evolution of neuroscience innovation. #bms #neurentis #neuroscience #neuroscienceresearch #researchanddevelopment #research #brainhealth #psychiatry #neurodegenerativedisease #autism #depression #neuropsychiatry #mentalhealth #health #futureofhealthcare #futureofhealth #futureofbusiness #addiction #alcohol #alzheimersdisease #alzheimers #biomarkers #earlydetection #earlydiagnosis #diagnosticpathway #patientjourney #cognitiveimpairment #cognitivedecline #neuroimaging #clinicalresearch #brainresearch #neurology #patientcare #longtermcare #insuranceindustry #precisionmedicine #drugdevelopment #omics #genetics #genomics #genomicmedicine #genomicresearch #science #scientist #researchimpact #researchneverstops #breakthrough #innovation #academicexcellence #imaging #prognosis #enrichment #realworldevidence #realworlddata #dementia #datascience #lifesciences #medicine #systemsbiology #parkinsonsdisease #multiplesclerosis #schizophrenia #bipolardisorder #als #epilepsy #sleep #clinicaltrials #ataxia #neuroinflammation #huntingtonsdisease #pathology #microglia #tau #synapse https://lnkd.in/e3z7_ht3

Global Genetic Insights into Problematic Alcohol Use December 26, 2023 A groundbreaking study led by VA Connecticut Healthcare Center/Yale researchers uncovers a shared genetic basis for problematic alcohol use (PAU) across diverse ancestries. This global genetic exploration broadens our understanding of PAU's genetic architecture, identifying 110 risk gene regions with potential drug targets for future treatments. Key Findings 1. Shared Genetic Architecture: Over 1 million individuals from diverse genetic backgrounds participated in this study, revealing a shared genetic foundation for PAU. 2. Targeted Insights: The research identifies 110 risk gene regions, offering insights into PAU biology and potential pharmacological targets for innovative interventions. 3. Potential Treatments: Existing medications show promise as potential treatments for PAU, opening avenues for future studies. The study also explores genetic correlations with other mental and neurological disorders. Source: Yale This study, the largest to date for PAU, emphasizes the importance of understanding the molecular mechanisms behind PAU. Dr. Hang Zhou, the lead researcher, notes that this knowledge is crucial for future treatments, potentially mitigating the consequences of excessive alcohol use. Million Veteran Program (MVP): The study leverages data from MVP, combining it with other sources to create comprehensive analyses. Cross-ancestry information enhances the power of gene discovery, fostering a better understanding of PAU biology. Cross-Ancestry Insights: While there are genetic differences in PAU across populations, the study emphasises the substantial shared genetic architecture. This global perspective allows for improved fine-mapping of potential causal variants. Towards Future Treatments: The research not only uncovers potential drug targets but also paves the way for future functional analyses and drug development. Drug-repurposing analyses highlight existing medications as potential treatments for PAU. At Neurentis, we are committed to advancing mental health solutions. Currently, we're developing a treatment for alcohol addiction, aligning with the latest advancements in genetic research. Stay tuned for our contributions to this critical field. https://lnkd.in/dbHauVWc Read the full study in Nature Medicine. https://lnkd.in/dehp6QYs #MentalHealth #Genetics #AlcoholUse #Neuroscience #Research #Neurentis #addiction #pharmaceuticals #drugdevelopment

Big Deals in Neuroscience! AbbVie's $8.7B Deal with Cerevel Highlights Pharma's Pursuit of Innovation. Breaking News in Neuroscience! AbbVie, a pharmaceutical giant, is investing $8.7 billion in the acquisition of Cerevel Therapeutics, underlining the industry's keen interest in groundbreaking treatments. Highlights: 1. Broadening Neuro Portfolio: AbbVie's substantial investment in Cerevel expands its neuroscience assets, encompassing migraine, movement disorders, and psychiatric disorders, including a novel treatment for schizophrenia currently in phase 2 testing. 2. Strategic Growth: AbbVie's CEO, Richard Gonzalez, sees Cerevel as a growth opportunity that extends well into the next decade. The move aligns with AbbVie's commitment to leveraging commercial capabilities, global infrastructure, and clinical expertise for substantial shareholder value. 3. Cerevel's Pipeline: Cerevel's promising pipeline includes emraclidine, undergoing phase 2 trials for schizophrenia and Alzheimer’s disease psychosis. This aligns with the industry trend of exploring innovative solutions for complex neurological conditions. 4. Bold Decision-Making: AbbVie's decision to acquire Cerevel before complete trial data is a bold strategic move, avoiding potential bidding wars and securing a valuable position in case trial results surpass expectations. Neurentis in the Spotlight: As we've highlighted, big pharma companies are actively seeking novel solutions in neuroscience. Neurentis, a player in this space, is contributing to the evolving landscape with its innovative approaches to mental health, autism, chronic pain, and addiction. The race for cutting-edge treatments in neuroscience is heating up, and Neurentis is at the forefront of this exciting wave of innovation. More news coming soon ! #neuroscience #pharma #biotech #deals #acquisitions #collaboration #alliances #abbvie #neurentis https://lnkd.in/evr6Q9ed

Exercise's Hidden Power Against Alzheimer's. Alzheimer's Defense through Exercise!Groundbreaking research reveals an exercise-induced hormone, irisin, significantly reduces amyloid beta levels linked to Alzheimer's disease. In a recent study by Massachusetts General Hospital, researchers found that irisin treatment led to a remarkable reduction in amyloid beta pathology. This effect was attributed to increased neprilysin activity, a crucial amyloid beta-degrading enzyme, released by astrocytes in the brain. Exercise is a powerful tool in promoting brain health, and understanding how it produces hormones like irisin may pave the way for innovative therapies against Alzheimer's disease. Exercise has long been associated with reduced amyloid beta deposits, and irisin, the muscle-derived hormone elevated during physical activity, may hold the key to this connection. The study identified integrin αV/β5 as the receptor binding to irisin on astrocytes, triggering increased neprilysin levels. Moreover, irisin's binding to this receptor diminishes signaling in pathways involving extracellular signal-regulated kinase (ERK) and signal activator of transcription 3 (STAT3), which is critical for irisin-induced enhancement of neprilysin. These findings suggest that irisin could be a crucial mediator of exercise-induced increases in neprilysin levels, offering a potential target for Alzheimer's prevention and treatment. Connect the Dots: Neurentis in Action At Neurentis, we are committed to advancing neuroscience research. Our work aligns with the pursuit of innovative solutions for mental health challenges. Learn more about our initiatives at https://neurentis.com Reference: Exercise-Induced Hormone Irisin May Reduce Alzheimer’s Disease Plaque and Tangle Pathology in the Brain. (8 September 2023) Massachusetts General Hospital. [https://lnkd.in/eBMnBjtN] #alzheimersdisease #alzheimers #alzheimersresearch #treatment #dementia #drugdevelopment #neuroscience #massachusetts

Unveiling Insights into Alzheimer's Disease: Serotonin's Role in Cognitive Decline. Exciting findings from @HopkinsMedicine shed light on the connection between serotonin loss and early-stage Alzheimer's disease. Key Takeaways: 1. **Serotonin & Memory:** The study reveals a correlation between lower serotonin levels and memory problems in mild cognitive impairment (MCI), a stage between normal aging and Alzheimer's disease (AD). Serotonin, known as the "happiness" chemical, plays a crucial role in mood, appetite, and sleep. 2. **Early Predictive Markers:** Changes in serotonin transporter levels were identified in MCI patients, indicating measurable brain changes before an AD diagnosis. This insight opens avenues for predictive markers and early intervention strategies. 3. **Potential for Treatment:** Researchers suggest that targeting serotonin loss may be a safe and effective way to improve cognitive deficits and alleviate depressive symptoms associated with AD. Antidepressant medications could play a crucial role in slowing disease progression. 4. **Neurentis’ Commitment:** Neurentis is actively engaged in neuroscience research, striving to contribute meaningful solutions to mental health challenges. Our commitment aligns with the industry's pursuit of innovative treatments for neurodegenerative disorders. Let's continue supporting advancements in neuroscience research for a brighter and healthier future! #neuroscience #depression #depressionawareness #mentalhealth #mentalhealthmatters #biotech #pharma #pharmaceuticals #serotonin #alzheimersdisease #alzheimers #alzheimersresearch #antidepressants #mci #treatment #neurentis Reference: Study Suggests Serotonin Loss May Contribute to Cognitive Decline in the Early Stages of Alzheimer's Disease. (Dec 7, 2023) @HopkinsMedicine. [https://lnkd.in/dESeReMx]

Managing stress is key for a healthy heart! Harvard Health shares 5 effective ways to de-stress: 1️⃣ Stay Positive: Laughter lowers stress hormones, reduces inflammation, and boosts "good" HDL cholesterol. 2️⃣ Meditate: Practice deep breathing to reduce heart disease risk factors like high blood pressure. 3️⃣ Exercise: Physical activity releases mood-boosting endorphins, protects against heart disease, and promotes overall well-being. 4️⃣ Unplug: Escape from constant stress by disconnecting from emails and news; take daily moments for yourself. 5️⃣ Find Ways to Destress: Enjoy a warm bath, listen to music, or indulge in a favourite hobby to take a break from life's stressors. Taking small steps daily can make a big difference in your heart health. #stress #stressrelief #stressmanagement #anxietyrelief #anxiety #mentalhealth https://lnkd.in/eMWgbFj?

Unlocking the Secrets of Depression: A Multi-Omics Breakthrough Recent research to be published in the Journal of Affective Disorders (Volume 344, 1 January 2024) sheds new light on major depressive disorder (MDD), a chronic mental illness affecting millions worldwide. The study delves into the intricate interplay of gut microbiota and metabolic phenotype in unmedicated MDD patients, revealing fascinating insights into the biological underpinnings of this complex condition. Global Impact of Depression Depression poses a significant global health challenge, impacting not only mental well-being but also giving rise to physical symptoms like loss of appetite, fatigue, insomnia, and cognitive difficulties. The burden of MDD extends beyond individuals, affecting families and straining societal resources. Metabolomics Unveils Discrepancies Employing advanced UPLC-Q/TOF-MS technology, the researchers conducted metabolomic analyses of serum and urine from 57 unmedicated MDD patients and 57 healthy controls. Striking differences emerged in glycerophospholipid metabolism, bile acid biosynthesis, and amino acid pathways, offering a nuanced view of the metabolic disturbances associated with MDD. Diagnostic Biomarkers on the Horizon The study identified potential diagnostic biomarkers, including carnitine and specific fatty acid classes, opening avenues for more precise diagnostic tools. These markers hold promise for improving the accuracy and efficiency of MDD diagnosis, a critical step towards personalized treatment. The Gut-Brain Axis Connection Notably, the research explored disruptions in the gut microbiota of MDD patients. The observed imbalance in Firmicutes/Bacteroidetes ratio and changes at the genus level highlights the intricate relationship between gut health and mental well-being. Implications for Future Treatment Understanding the symbiotic relationship between the gut and brain could revolutionise future treatments. Targeting the gut microbiota to optimise its structure may offer new avenues for preventing and treating depression, presenting a paradigm shift in mental health interventions. Insights into MDD By combining metabolomic data with gut microbiota analysis, this study provides a more integrated understanding of MDD. Such insights are crucial for unraveling the complexities of depression and paving the way for more effective interventions. Read the Full Study: Characteristics of gut microbiota and metabolic phenotype in patients with major depressive disorder https://lnkd.in/dJHMjPn4 #depression #depressionawareness #depressiontreatment #mdd #mentalhealth #mentalhealthmatters #mentalillness #treatment #neurentis

Neuroscience Takes Centre Stage: AbbVie's Strategic Move in Parkinson’s Disease AbbVie's recent acquisition of Mitokinin, a neuroscience biotech company with a focus on Parkinson's disease (PD), underscores the growing significance of neuroscience in the pharmaceutical landscape. Valued at over $650 million, this deal amplifies the industry's recognition of the urgent need for innovative treatments targeting neurological disorders. The neuroscience sector has become a focal point for major pharmaceutical-biotech collaborations, with companies like Merck and Novartis making substantial investments in neurodegenerative disease-focused entities. Merck's acquisition of Caraway Therapeutics for up to $610 million and Novartis' deal with DTx Pharma for up to $1 billion highlight a trend of pharma giants seeking to bolster their portfolios in the realm of neuroscience. The prevalence of conditions like PD, affecting over 8.5 million individuals worldwide, amplifies the demand for groundbreaking treatments. AbbVie's strategic move to access Mitokinin's PINK1 activator, designed to address mitochondrial dysfunction—a contributing factor to PD—underscores the pharmaceutical industry's commitment to exploring novel avenues for neurological disorders. As the global burden of neurological diseases continues to rise, pharmaceutical companies are actively seeking partnerships and acquisitions to fill the void in treatment options. The challenges posed by conditions such as PD, Alzheimer's, and depression necessitate a collaborative approach, prompting industry leaders to invest significantly in promising biotech ventures. AbbVie's foray into Mitokinin's innovative approach serves as a testament to the pharmaceutical industry's collective effort to develop transformative solutions for unmet medical needs in neuroscience. The string of recent deals in this space reflects a shared commitment to advancing research and bringing novel therapies to the forefront, addressing the pressing health challenges posed by neurological disorders. In this landscape of evolving partnerships and acquisitions, the momentum in neuroscience research highlights not only the scientific advancements but also the strategic imperatives for pharma companies to stay at the forefront of innovation in tackling complex neurological conditions. #neuroscience #neurology #mentalhealth #pharma #biotech #deals #dealmaking #acquisitions #merck #neurentis https://lnkd.in/dD6rahRE